Key issues in perioperative treatment of gastric cancer in the era of immunotherapy
DING Xue-wei
LIANG Han
Abstract：Immunotherapy represented by PD-1/PD-L1 monoclonal antibody has significantly improved the survival outcome of patients with advanced gastric cancer.Neoadjuvant chemotherapy+D2 radical resection for gastric cancer is one of the current standard treatment strategies for gastric cancer.In recent years,a number of studies on perioperative chemotherapy combined with immunotherapy for gastric cancer have shown that perioperative chemotherapy+immunotherapy significantly improves the pCR rate.The ATTRACTION-5 and KEYNOTE585 studies did not meet expectations,and the short-term efficacy of MATTERHONE is more significant and worth looking forward to.The screening of immunodominant populations and precision treatment are the main problems of perioperative immunotherapy.
Keywords：locally advanced gastric cancerperioperative periodimmunotherapy
Publication Date：2024-10-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1095-1098 )